Drugs / acolbifene

Trials 3 · a red edge is where a trial was stopped

20092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 22 trials
Phase 2 NCT05941520 Oct 2024 → Aug 2027 expected ductal breast carcinoma in situ, lobular breast carcinoma in situ National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 2 NCT00853996 Feb 2009 → Dec 2010 breast cancer University of Kansas Medical Center Completed No outcome recorded
Phase 31 trial
Phase 3 NCT01452373 Oct 2011 → Dec 2012 EndoCeutics Inc. Completed No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as Acolbifene ClinicalTrials.gov intervention name — accepted as the source's own label NCT01452373
2

NCT00853996

NCT05941520

Known as Acolbifene hcl ChEMBL registry synonym — accepted as the source's own label CHEMBL68055
Known as acolbifene hydrochloride “Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.” NCT00853996
1

“Drug: Acolbifene HydrochlorideNCT05941520

Known as Acolbifeno ChEMBL registry synonym — accepted as the source's own label CHEMBL68055
Known as Em-652 ChEMBL registry synonym — accepted as the source's own label CHEMBL68055
Known as SCH-57068 ChEMBL registry synonym — accepted as the source's own label CHEMBL68055
Known as SCH-57068 HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL68055
Known as SCH57068 HCL ChEMBL registry synonym — accepted as the source's own label CHEMBL68055
Action Inhibit “Acolbifene and tamoxifen blocks the use of estrogen by breast cells.” NCT05941520
Modality Other / unclassified “acolbifene (a selective estrogen receptor modulator (SERM))” NCT01452373
Route Oral “Given orally” NCT00853996